ANVAENDNING AV AROMATASHAEMMARE OCH ANTIANDROGENER FOER FRAMSTAELLNING AV LAEKEMEDEL FOER PROFYLAX OCH TERAPI AV BENIGN PROSTATAHYPERPLASI

摘要

A combination of an aromatase-inhibitor and an antiandrogen in a weight ratio of aromatase-inhibitor to antiandrogen of 20:1 to 1:1 is useful in a method of prophylaxis and/or of treatment by therapy of prostatic hyperplasia. The aromatase-inhibitor is, for example, testolactone and the antiandrogen is, for example, cyproterone acetate.